|
Definite IgG4-RD (%)
|
9 (90%)
|
5 (100%)
| |
|
Probable IgG4-RD (%)
|
1 (10%)
|
0 (0%)
| |
|
Possible IgG4-RD (%)
|
0 (0%)
|
0 (0%)
| |
|
Age, yr, median
|
69 (60–71)
|
73 (64–80)
|
0.13
|
|
Male, n (%)
|
9 (90%)
|
3 (60%)
| |
|
Multiorgan involvement (> 1 organ)
|
7 (70%)
|
4 (80%)
| |
|
Baseline
|
|
ESR (0–20 mm/h)
|
10 (9–23)
|
15 (8–20)
|
0.59
|
|
CRP (< 6 mg/L)
|
5 (4–6.5)
|
10 (5–46)
|
0.06
|
|
IgG4-RD RI (0–3)
|
9 (6–9)
|
12 (9–12)
|
0.22
|
|
Eosinophils (< 300 cell/μl)
|
300 (300–500)
|
200 (150–300)
|
0.034
|
|
Serum IgG4 (< 135 mg/dl)
|
364 (232–1090)
|
498 (328–947)
|
0.5
|
|
IgE (mU/ml)
|
308 (2–1488)
|
733 (271–1554)
|
0.11
|
|
Prednisone dose (mg/d)
|
5 (0–5.5)
|
5 (2.5–5)
|
0.99
|
|
CD19+ B cells (cells/ml)
|
138,500 (97,500–172,500)
|
144,000 (103,000–162,000)
|
0.66
|
|
CD20+ B cells (cells/ml)
|
114,000 (86,250–150,000)
|
128,000 (82,000–140,500)
|
0.57
|
|
Naive B cells (cells/ml)
|
14,170 (9518–24,198)
|
11,170 (2915–38,650)
|
0.35
|
|
Percentage of CD19+ B cells
|
11.4 (9.5–13.7)
|
11.52 (2.33–24.37)
|
0.09
|
|
Memory B cells (cells/ml)
|
20,450 (10,790–36,070)
|
48,590 (11,305–62,095)
|
0.44
|
|
Percentage of CD19+ B cells
|
15.79 (10.25–23.9)
|
26.48 (6.9–47.88)
|
0.67
|
|
Plasmablasts (cells/ml)
|
3280 (985–9868)
|
5400 (3825–8000)
|
0.39
|
|
Percentage of CD19+ B cells
|
3.26 (0.84–7.8)
|
3.38 (2.06–4.82)
|
0.76
|
|
Plasma cells (cells/ml)a
|
420 (0–1332)
|
489 (146–1300)
|
0.86
|
|
Percentage of CD19+ B cellsa
|
0.37 (0–1.27)
|
0.27 (0.1–0.49)
|
0.95
|
|
After 6 mo of treatment
|
|
ESR (0–20 mm/h)
|
5 (3–21)
|
9 (8–20)
|
0.29
|
|
CRP (< 6 mg/L)
|
2 (1–2.25)
|
2 (1.5–4)
|
0.47
|
|
IgG4-RD RI (0–3)
|
2.5 (1.75–3.25)
|
2 (2–2.5)
|
0.62
|
|
Eosinophils (< 300 cell/μl)
|
200 (100–325)
|
100 (100–200)
|
0.37
|
|
Serum IgG4 (< 135 mg/dl)
|
182.5 (107–729)
|
257 (211–406)
|
0.42
|
|
IgE (mU/ml)
|
107 (2–299)
|
425 (384–466)
|
0.13
|
|
Prednisone dose (mg/d)
|
5 (0–5.62)
|
5 (2.5–5)
|
0.99
|
|
CD19+ B cells (cells/ml)
|
174,500 (93,750–222,250)
|
128,000 (64,500–157,500)
|
0.2
|
|
CD20+ B cells (cells/ml)
|
165,000 (84,750–208,500)
|
128,000 (52,500–154,000)
|
0.24
|
|
Naive B cells (cells/ml)
|
7860 (3988–13,585)
|
7380 (2950–15,460)
|
0.8
|
|
Percentage of CD19+ B cells
|
3.51 (2.57–4.13)
|
9.27 (4.16–15.73)
|
0.1
|
|
Memory B cells (cells/ml)
|
60,540 (21,148–75,428)
|
18,360 (9045–34,650)
|
0.05
|
|
Percentage of CD19+ B cells
|
27.46 (19.06–34.9)
|
24.19 (6.43–37.65)
|
0.89
|
|
Plasmablasts (cells/ml)
|
355 (138–1263)
|
1310 (565–3350)
|
0.07
|
|
Percentage of CD19+ B cells
|
0.27 (0.07–0.53)
|
0.88 (0.36–5.3)
|
0.03
|
|
Plasma cells (cells/ml)a
|
56 (0–333)
|
143 (0–423)
|
0.22
|
|
Percentage of CD19+ B cellsa
|
0.05 (0–0.32)
|
0.19 (0–0.53)
|
0.16
|
